The PTAB has instituted inter partes review of Genentech’s U.S. Patent 7,622,115, granting Hospira’s petition in IPR2016-01771.  According to the institution decision, the patent is directed to methods for treating cancer in a patient comprising administering an effective amount of bevacizumab and assessing the patient for gastrointestinal (“GI”) perforation during treatment with bevacizumab.  Bevacizumab is marketed under the trade-name Avastin®, and is indicated for treating colorectal, lung, glioblastoma, kidney, cervical, and ovarian cancer.

This institution decision is posted on our IPR tracker page along with other important filings for IPRs on biologic patents.